Vertex Pharmaceuticals slipped 1.41% to close at $475.49, managing to outperform a much gloomier market where the S&P 500 nose-dived 3.46%. Despite the drop, Vertex flexed its resilience, outpacing ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

Vertex Pharmaceuticals has been the apple of investors' search engines, but its recent stock dip of 3.3% might have folks ...

The stock's rise snapped a three-day losing streak.

In its first full year on the U.S. market, bladder cancer treatment Adstiladrin earned about $77 million. Elsewhere, Lilly ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...

As the industry awaits official word from the administration on how the tariffs will hit, analysts go over the possibilities ...

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean ...

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...